Literature DB >> 6716272

Comparison of diazepam and oxazepam: preference, liking and extent of abuse.

R R Griffiths, D R McLeod, G E Bigelow, I A Liebson, J D Roache, P Nowowieski.   

Abstract

In a residential hospital research ward setting, the effects of and preference for placebo, oxazepam (480 mg) and diazepam (40, 80 and 160 mg) were studied in human volunteers with histories of sedative drug abuse. Doses p.o. were administered every 3rd day under double-blind conditions. After an initial exposure to the letter-coded test drugs, a series of choice days was scheduled on which subjects chose between two available drug alternatives. Compared with oxazepam, diazepam produced greater liking (area under the time-action curve), peak liking and euphoria and was judged to be of greater monetary street value. Diazepam was categorized as producing barbiturate-like subjective effects more frequently than was oxazepam (54 vs. 21%), whereas oxazepam was identified as placebo more often than diazepam (32 vs. 4%). Diazepam was associated with a more rapid onset of effect than was oxazepam, and this rapid onset was repeatedly cited by subjects in poststudy written comments as being a desirable feature of the drug effect. In choice tests, 80 and 160 mg of diazepam were preferred to 480 mg of oxazepam on 62.5 and 91.7% of the choice tests, respectively. In choice tests between placebo and drug, placebo was never preferred to diazepam; however, placebo was preferred to oxazepam on 21.4% of choice tests. Overall, these results extend previous experimental observations suggesting that diazepam has a higher abuse liability than oxazepam. The results are also compatible with an analysis of epidemiological data showing that diazepam abuse uniformly exceeds oxazepam abuse on seven epidemiological measures of drug abuse.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6716272

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

1.  Preference for diazepam, but not buspirone, in moderate drinkers.

Authors:  S M Evans; R R Griffiths; H de Wit
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

Review 2.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

4.  A 5-year follow-up study of users of benzodiazepine: starting with diazepam versus oxazepam.

Authors:  Ingunn Fride Tvete; Trine Bjørner; Tor Skomedal
Journal:  Br J Gen Pract       Date:  2016-03-10       Impact factor: 5.386

5.  The behavioral actions of diazepam and oxazepam are similar.

Authors:  S P Mewaldt; M M Ghoneim; J V Hinrichs
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 6.  Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective.

Authors:  U Busto; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

7.  Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers.

Authors:  James P Zacny; Judith A Paice; Dennis W Coalson
Journal:  Pharmacol Biochem Behav       Date:  2011-11-04       Impact factor: 3.533

8.  Rate of increase of plasma drug level influences subjective response in humans.

Authors:  H de Wit; B Bodker; J Ambre
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  Subjective and behavioral effects of diazepam depend on its rate of onset.

Authors:  H de Wit; S Dudish; J Ambre
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Relative abuse liability of diazepam and oxazepam: behavioral and subjective dose effects.

Authors:  R R Griffiths; D R McLeod; G E Bigelow; I A Liebson; J D Roache
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.